Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Enjaymo™ (sutimlimab-jome) – Updated indication
January 25, 2023 - The FDA approved a revised indication for Sanofi’s Enjaymo (sutimlimab-jome), for the treatment of hemolysis in adults with cold agglutinin disease (CAD).
